Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptacog Alfa for Rebleeding After ICH Surgery
NCT00128050Phase 2Completed
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Jan 2005
- Primary completion
- Dec 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in intracerebral hemorrhage (ICH) comparing NovoSeven with Placebo (2 arms). Primary endpoint: Efficacy of Eptacog alfa in preventing or reducing rebleeding (Hematoma Volume). Started Jan 2005; status: completed.
02
Drugs
coagulation factor VIIa
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT00128050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00128050.